Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin

American Journal of Physiology - Cell Physiology

Volumn 292, Issue 4, 2007, Pages

  Osborn, Teresia M ^a,b   Dahlgren, Claes ^b   Hartwig, John H ^a   Stossel, Thomas P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Neutrophils; P selectin; Peptide; Superoxide production

Indexed keywords

ACTIN; ALBUMIN; GELSOLIN; ISOPROTEIN; LYSOPHOSPHATIDIC ACID; PADGEM PROTEIN; RECOMBINANT PROTEIN; SUPEROXIDE; THROMBOCYTE ACTIVATING FACTOR;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE ACTIVATION; MEDIATOR RELEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; THROMBOCYTE ACTIVATION; TISSUE INJURY; UPREGULATION;

BLOOD PLATELETS; GELSOLIN; HUMANS; LYSOPHOSPHOLIPIDS; NEUTROPHILS; OLIGOPEPTIDES; P-SELECTIN; PLATELET ACTIVATING FACTOR; RECOMBINANT PROTEINS; SUPEROXIDES; UP-REGULATION;

ANIMALIA;

EID: 34247349431     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00510.2006     Document Type: Article

References (58)

1. Barkalow K, Witke W, Kwiatkowski D, Hartwig J. Coordinated regulation of platelet actin filament barbed ends by gelsolin and capping protein. J Cell Biol 134: 389-399, 1996.
2. Boyum A, Lovhaug D, Tresland L, Nordlie EM. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand J Immunol 34: 697-712, 1991.
3. Bucki R, Georges PC, Espinassous Q, Funaki M, Pastore JJ, Chaby R, Janmey PA. Inactivation of endotoxin by human plasma gelsolin. Biochemistry 44: 9590-9597, 2005.
4. Chauhan VP, Ray I, Chauhan A, Wisniewski HM. Binding of gelsolin, a secretory protein, to amyloid beta-protein. Biochem Biophys Res Commun 258: 241-246, 1999.
5. Christofidou-Solomidou M, Scherpereel A, Solomides CC, Christie JD, Stossel TP, Goelz S, DiNubile MJ. Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J Investig Med 50: 54-60, 2002.
6. Christofidou-Solomidou M, Scherpereel A, Solomides CC, Muzykantov VR, Machtay M, Albelda SM, DiNubile MJ. Changes in plasma gelsolin levels during acute oxidant lung injury in mice. Lung 180: 91-104, 2002.
7. Clay KL, Johnson C, Henson P. Binding of platelet activating factor to albumin. Biochim Biophys Acta 1046: 309-314, 1990.
8. Cooke NE, Haddad JG. Vitamin D binding protein (Gc-globulin). Endocr Rev 10: 294-307, 1989.
9. Cunningham CC, Vegners R, Bucki R, Funaki M, Korde N, Hartwig JH, Stossel TP, Janmey PA. Cell permeant polyphosphoinositide-binding peptides that block cell motility and actin assembly. J Biol Chem 276: 43390-43399, 2001.
10. Dahl B, Schiodt FV, Ott P, Gvozdenovic R, Yin HL, Lee WM. Plasma gelsolin is reduced in trauma patients. Shock 12: 102-104, 1999.
11. Dahlgren C, Karlsson A. Respiratory burst in human neutrophils. J Immunol Methods 232: 3-14, 1999.
12. Dhainaut JF, Tenaillon A, Hemmer M, Damas P, Le Tulzo Y, Radermacher P, Schaller MD, Sollet JP, Wolff M, Holzapfel L, Zeni F, Vedrinne JM, de Vathaire F, Gourlay ML, Guinot P, Mira JP. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 26: 1963-1971, 1998.
13. DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood 100: 4367-4371, 2002.
14. Dueland S, Nenseter MS, Drevon CA. Uptake and degradation of filamentous actin and vitamin-D binding protein in the rat. Biochem J 274: 237-241, 1991.
15. Erukhimov JA, Tang ZL, Johnson BA, Donahoe MP, Razzack JA, Gibson KF, Lee WM, Wasserloos KJ, Watkins SA, Pitt BR. Actincontaining sera from patients with adult respiratory distress syndrome are toxic to sheep pulmonary endothelial cell. Am J Respir Crit Care Med 162: 288-294, 2000.
16. Falet H, Pain S, Rendu F. Tyrosine unphosphorylated platelet SHP-1 is a substrate for calpain. Biochem Biophys Res Commun 252: 51-55, 1998.
17. Feng L, Mejillano M, Yin HL, Chen J, Prestwich GD. Full-contact domain labeling: identification of a novel phosphoinositide binding site on gelsolin that requires the complete protein. Biochemistry 40: 904-913, 2001.
18. Fischer DJ, Nusser N, Virag T, Yokoyama K, Wang D, Baker DL, Bautista D, Parrill AL, Tigyi G. Short-chain phosphatidates are subtypeselective antagonists of lysophosphatidic acid receptors. Mol Pharmacol 60: 776-784, 2001.
19. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334: 1697-1702, 1996.
20. Goetzl EJ, Lee H, Azuma T, Stossel TP, Turck CW, Karliner JS. Gelsolin binding and cellular presentation of lysophosphatidic acid. J Biol Chem 275: 14573-14578, 2000.
21. Graler MH, Goetzl EJ. Lysophospholipids and their G protein-coupled receptors in inflammation and immunity. Biochim Biophys Acta 1582: 168-174, 2002.
22. Haddad JG, Harper KD, Guoth M, Pietra GG, Sanger JW. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci USA 87: 1381-1385, 1990.
23. Hama K, Bandoh K, Kakehi Y, Aoki J, Arai H. Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors. FEBS Lett 523: 187-192, 2002.
24. Haseruck N, Erl W, Pandey D, Tigyi G, Ohlmann P, Ravanat C, Gachet C, Siess W. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood 103: 2585-2592, 2004.
25. Huang S, Rhoads SL, DiNubile MJ. Temporal association between serum gelsolin levels and clinical events in a patient with severe falciparum malaria. Clin Infect Dis 24: 951-954, 1997.
26. Izumi T, Shimizu T. Platelet-activating factor receptor: gene expression and signal transduction. Biochim Biophys Acta 1259: 317-333, 1995.
27. Janmey PA, Lind SE, Yin HL, Stossel TP. Effects of semi-dilute actin solutions on the mobility of fibrin protofibrils during clot formation. Biochim Biophys Acta 841: 151-158, 1985.
28. Janmey PA, Stossel TP. Modulation of gelsolin function by phosphatidylinositol 4,5-bisphosphate. Nature 325: 362-364, 1987.
29. Kouyama T, Mihashi K. Fluorimetry study of N-(1-pyrenyl) iodoacetamide-labelled F-actin. Local structural change of actin protomer both on polymerization and on binding of heavy meromyosin. Eur J Biochem 114: 33-38, 1981.
30. Kwiatkowski DJ, Stossel TP, Orkin SH, Mole JE, Colten HR, Yin HL. Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature 323: 455-458, 1986.
31. Lee PS, Drager LR, Stossel TP, Moore FD, Rogers SO. Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann Surg 243: 399-403, 2006.
32. Lee PS, Waxman AB, Cotich BA, Chung SW, Perrella MA, Stossel TP. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med. First published Jan. 3, 2007; 10.1097/01.CCM.0000253815.26311.24.
33. Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin toxicity. N Engl J Med 326: 1335-1341, 1992.
34. Lind SE, Smith DB, Janmey PA, Stossel TP. Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury. Am Rev Respir Dis 138: 429-434, 1988.
35. Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J Clin Invest 78: 736-742, 1986.
36. Lopez Diez F, Nieto ML, Fernandez-Gallardo S, Gijon MA, Sanchez Crespo M. Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Clin Invest 83: 1733-1740, 1989.
37. Ludwig JC, Hoppens CL, McManus LM, Mott GE, Pinckard RN. Modulation of platelet-activating factor (PAF) synthesis and release from human polymorphonuclear leukocytes (PMN): role of extracellular albumin. Arch Biochem Biophys 241: 337-347, 1985.
38. 2+. Arch Biochem Biophys 232: 102-110, 1984.
39. Mariano F, Guida G, Donati D, Tetta C, Cavalli PL, Verzetti G, Piccoli G, Camussi G. Production of platelet-activating factor in patients with sepsis-associated acute renal failure. Nephrol Dial Transplant 14: 1150-1157, 1999.
40. Meerschaert K, De Corte V, De Ville Y, Vandekerckhove J, Gettemans J. Gelsolin and functionally similar actin-binding proteins are regulated by lysophosphatidic acid. EMBO J 17: 5923-5932, 1998.
41. Mere J, Chahinian A, Maciver SK, Fattoum A, Bettache N, Benyamin Y, Roustan C. Gelsolin binds to polyphosphoinositide-free lipid vesicles and simultaneously to actin microfilaments. Biochem J 386: 47-56, 2005.
42. Mounzer KC, Moncure M, Smith YR, DiNubile MJ. Relationship of admission gelsolin levels to clinical outcomes in patients after major trauma. Am J Resp Dis Crit Care Med 160: 1673-1681, 1999.
43. Nieto ML, Velasco S, Sanchez Crespo M. Biosynthesis of plateletactivating factor in human polymorphonuclear leukocytes. Involvement of the cholinephosphotransferase pathway in response to the phorbol esters. J Biol Chem 263: 2217-2222, 1988.
44. Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J, Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis (COMPASS) Investigators. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 32: 332-341, 2004.
45. Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, Lee WM, Horton JW, Yin HL, Turnage RH. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol 96: 25-31, 2004.
46. Schuster DP, Metzler M, Opal S, Lowry S, Balk R, Abraham E, Levy H, Slotman G, Coyne E, Souza S, Pribble J, Pafase ARDS Prevention Study Group. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 31: 1612-1619, 2003.
47. Siess W, Tigyi G. Thrombogenic and atherogenic activities of lysophosphatidic acid. J Cell Biochem 92: 1086-1094, 2004.
48. Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol Cell Physiol 259: C697-C708, 1990.
49. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 40: 643-672, 2003.
50. Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med 25: 594-598, 1997.
51. Suputtamongkol Y, Intaranongpai S, Smith MD, Angus B, Chaowagul W, Permpikul C, Simpson JA, Leelarasamee A, Curtis L, White NJ. A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrob Agents Chemother 44: 693-696, 2000.
52. Thumser AE, Voysey JE, Wilton DC. The binding of lysophospholipids to rat liver fatty acid-binding protein and albumin. Biochem J 301: 801-806, 1994.
53. Tigyi G, Miledi R. Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells. J Biol Chem 267: 21360-21367, 1992.
54. Tigyi G, Parrill AL. Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res 42: 498-526, 2003.
55. Vartanian AA. Gelsolin and plasminogen activator inhibitor-1 are Ap3A-binding proteins. Ital J Biochem 52: 9-16, 2003.
56. Wen D, Corina K, Chow EP, Miller S, Janmey PA, Pepinsky RB. The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry 35: 9700-9709, 1996.
57. Zeng S, Yi FX, Guo ZG. Platelet activating factor-induced P-selectin expression in platelets and its related signal transduction. Zhongguo Yao Li Xue Bao 20: 948-950, 1999.
58. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 30: S294-S301, 2002.